ScholarIQanswers from OpenAlex & ORCID
Thomas J. Herzog
ResearcherPublications, citations & collaboration network
Thomas J. Herzog is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Thomas J. Herzog have?
ScholarIQindexed works
Thomas J. Herzog has 517 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Thomas J. Herzog have?
ScholarIQcitation count
Thomas J. Herzog has 21,116 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Thomas J. Herzog?
ScholarIQh-index
Thomas J. Herzog has an h-index of 75 in OpenAlex.
What is the i10-index of Thomas J. Herzog?
ScholarIQi10-index
Thomas J. Herzog has an i10-index of 261 in OpenAlex.
What is the ORCID of Thomas J. Herzog?
ScholarIQorcid
The ORCID for Thomas J. Herzog is on the source record.
What is the OpenAlex record for Thomas J. Herzog?
ScholarIQopenalex
The OpenAlex for Thomas J. Herzog is on the source record.
What are the most-cited papers on Thomas J. Herzog?
ScholarIQmost cited works
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
Mansoor Raza Mirza, Dana M. Chase, Brian M. Slomovitz, René dePont Christensen, Zoltán Novàk, Destin Black, Lucy Gilbert, Sudarshan Sharma, Giorgio Valabrega, Lisa M. Landrum, Lars Hanker, Ashley Stuckey, Ingrid Boere, Michael A. Gold, Annika Auranen, Bhavana Pothuri, David Cibula, Carolyn K. McCourt, Francesco Raspagliesi, Mark S. Shahin, Sarah Gill, Bradley J. Monk, Joseph Buscema, Thomas J. Herzog, Larry J. Copeland, Min Tian, Zangdong He, Shadi Stevens, Eleftherios Zografos, Robert L. Coleman, Matthew A. Powell
Nationwide Trends in the Performance of Inpatient Hysterectomy in the United States
Jason D. Wright, Thomas J. Herzog, Jennifer Tsui, Cande V. Ananth, Sharyn N. Lewin, Yu‐Shiang Lu, Alfred I. Neugut, Dawn L. Hershman
Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
Robert L. Coleman, Mark F. Brady, Thomas J. Herzog, Paul Sabbatini, Deborah K. Armstrong, Joan L. Walker, Byoung‐Gie Kim, Keiichi Fujiwara, Krishnansu S. Tewari, David M. O’Malley, Susan A. Davidson, Stephen C. Rubin, Paul DiSilvestro, Karen Basen‐Engquist, Helen Huang, John K. Chan, Nick M. Spirtos, Raheela Ashfaq, Robert S. Mannel
Robotically Assisted vs Laparoscopic Hysterectomy Among Women With Benign Gynecologic Disease
Jason D. Wright, Cande V. Ananth, Sharyn N. Lewin, William M. Burke, Yu‐Shiang Lu, Alfred I. Neugut, Thomas J. Herzog, Dawn L. Hershman
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
Krishnansu S. Tewari, Robert A. Burger, Danielle Enserro, Barbara M. Norquist, Elizabeth M. Swisher, Mark F. Brady, Michael A. Bookman, Gini F. Fleming, Helen Huang, Howard D. Homesley, Jeffrey M. Fowler, Benjamin E. Greer, Matthew Boente, Sharon X. Liang, Chenglin Ye, Carlos Bais, Leslie M. Randall, John K. Chan, J. Stuart Ferriss, Robert L. Coleman, Carol Aghajanian, Thomas J. Herzog, Philip J. DiSaia, Larry J. Copeland, Robert S. Mannel, Michael J. Birrer, Bradley J. Monk